In terms of safety, the PROSELICA [40] and FIRSTANA [41] trials, which did not allow prophylactic G‐CSF from cycle 1, reported that patients receiving cabazitaxel at a lower dose (20 vs. 25 mg/m2) had fewer cases of grade ≥ 3 neutropenia (PROSELICA: 41.8% vs. 73.3%; FIRSTANA: 37.8% vs. 70.6%) and febrile neutropenia (PROSELICA: 2.1% vs. 9.1%; FIRSTANA: 2.4% vs. 12.0%). Here, CSF3 is linked to neutropenia.